Clinical trials: Tumor Necrosis Factor-alpha
Myofacial Pain Syndrome
Dry Needling and Low-Level Laser Microcurrent Electrical Stimulation for Myofascial Pain Syndrome
This study aims to evaluate the effectiveness of dry needling and Low-Level Laser Microcurrent Electrical Stimulation (LL MCES) in patients with acute upper trapezius myofascial pain syndrome (MPS) by assessing both biological…
- Trial name
- NCT07750392
- Testing
- Dry Needle, Low-Level Laser Microcurrent Electrical Stimulation
- Where
- Indonesia
- Volunteers
- 80 people
- Sponsor
- Udayana University
Psoriasis
Study of Tumor Necrosis Factor Receptor Fusion Protein Etanercept (Enbrel) in Psoriasis of the Hands and/or Feet
The purpose of this research study is to see how well (compared to placebo) Enbrel® (etanercept) 50 mg twice a week for 12 weeks affects plaque psoriasis of the hands and/or feet (palmoplantar psoriasis).
- Trial name
- NCT00585650
- Testing
- Etanercept
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- University of California, Irvine
Sepsis at Intensive Care Unit
Clinical Study Evaluating the Efficacy and Safety of Colchicine in Adult Patients With Sepsis
Inflammatory markers are found to be an important contributor in sepsis. We evaluate the effect of colchicine on inflammatory processes and its possible protective effect against oxidative stress and organ dysfunction in adult…
- Trial name
- NCT07074990
- Testing
- conventional sepsis therapy alone, colchicine 500 mcg oral twice daily plus conventional sepsis therapy.
- Where
- Egypt
- Volunteers
- 46 people
- Sponsor
- Tanta University
Crohn Disease
Study on the Long-Term Risk of Recurrence of Anoperineal Fistula in Crohn's Disease
This research aims to evaluate the long-term recurrence risk of perianal fistulas in Crohn's disease patients who have undergone treatment with anti-TNF therapy and seton drainage.The research seeks to identify factors…
- Trial name
- LT-SAFCD (NCT06514092)
- Testing
- anti-TNF therapy and seton drainage
- Where
- France
- Volunteers
- 63 people
- Sponsor
- University Hospital, Toulouse
Arthritis, Psoriatic
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response
This is a study to confirm the clinical efficacy and safety of sonelokimab compared with placebo in the treatment of adults with active psoriatic arthritis who have had a previous inadequate response or intolerance to anti-tumor…
- Trial name
- IZAR-2 (NCT06641089)
- Testing
- Sonelokimab, Risankizumab
- Where
- 143 sites in United States, Bulgaria and 9 more
- Volunteers
- 600 people
- Sponsor
- MoonLake Immunotherapeutics AG
Rheumatoid Arthritis
Atacicept in Anti-Tumor Necrosis Factor Alpha-naïve Subjects With Rheumatoid Arthritis (AUGUST II)
The primary objective of this study is to evaluate the efficacy of atacicept compared to placebo in the treatment of signs and symptoms in a subject population with active rheumatoid arthritis (RA), inadequate response to…
- Trial name
- AUGUST II (NCT00595413)
- Testing
- Atacicept: with loading dose, Atacicept, Adalimumab
- Where
- 2 sites in United States, Germany
- Volunteers
- 311 people
- Sponsor
- EMD Serono
Inflammatory Bowel Disease (Crohn's Disease; Ulcerative Colitis), Adherence, Patient
Treatment Adherence Among Patients With Inflammatory Bowel Disease Receiving Anti-TNF Therapy
Inflammatory bowel disease (IBD) is a chronic condition characterized by periods of remission and relapse, requiring long-term treatment adherence to maintain disease control and prevent complications.
- Conditions
- Inflammatory Bowel Disease (Crohn's Disease; Ulcerative Colitis), Adherence, Patient, Structured Education
- Trial name
- NCT07652840
- Testing
- Health Belief Model-Based Structured Patient Education, Standard Patient Education
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 140 people
- Sponsor
- Izmir Katip Celebi University
Spondylitis, Ankylosing
Blocking Tumor Necrosis Factor in Ankylosing Spondylitis
The Division of Rheumatology at University of California San Francisco is conducting a research study on the treatment of ankylosing spondylitis (AS) with a new therapy currently used for people with other forms of arthritis.
- Trial name
- NCT00000433
- Testing
- Anti-Tumor Necrosis Factor
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Arthritis, Rheumatoid
Effectiveness and Safety of Yisaipu Combined With Tripterygium Wilfordii for Active RA
In this 24-week, multi-center, randomized, double-blind study, the investigators will evaluate the efficacy and safety profile of subcutaneously injected Yisaipu, a Tumor Necrosis Factor Receptor Fusion Protein, combined with…
- Trial name
- YISTAR (NCT03589833)
- Testing
- Tripterygium Wilfordii, Methotrexate, Yisaipu
- Where
- China
- Volunteers
- 504 people
- Sponsor
- Peking Union Medical College Hospital
Graft Versus Host Disease, Acute, Hematopoietic Stem Cell Transplantation
Infliximab Efficacy, TDM and Serum TNFα Levels in Pediatric HSCT Recipients With aGVHD: Prospective Observational Study
In children receiving a hematopoietic stem cell transplant (HSCT), blood levels of TNFalpha (an inflammatory cytokine) at the onset of the acute GVHD (graft-versus-host disease) could be correlated with the severity of the…
- Trial name
- NCT05362630
- Where
- Italy
- Volunteers
- 28 people
- Sponsor
- University of Pisa
Crohn Disease
A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease
The purpose of this study is to evaluate the efficacy and safety of JNJ-64304500 as add-on therapy to standard of care (SOC) biologic treatment with anti-tumor necrosis factor alpha or anti-interleukin 12/23 inhibitors in…
- Trial name
- DUET (NCT04655807)
- Testing
- JNJ-64304500, Adalimumab, Ustekinumab
- Where
- United States
- Sponsor
- Janssen Research & Development, LLC
Uveitis
Adalimumab in Uveitis Refractory to Conventional Therapy (ADUR Trial)
TNF alpha Inhibitors have been very effective in treating rheumatologic diseases as well as uveitis. Adalimumab is the first member of a new class of TNF antibody compounds developed to contain exclusively human sequences.
- Trial name
- NCT00348153
- Testing
- Adalimumab
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Heidelberg University
Crohn's Disease, IBD
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
This study (UNITI-1) will compare the effects (both positive and negative) of an initial treatment with ustekinumab to placebo over 8 weeks, in patients with moderately to severely active Crohn's disease who have either failed or…
- Conditions
- Crohn's Disease, IBD, Colitis, Inflammatory Bowel Disease
- Trial name
- NCT01369329
- Testing
- Group 2 ustekinumab 130 mg, Group 3: ustekinumab approximately 6 mg/kg
- Where
- 175 sites in United States, Australia and 21 more
- Volunteers
- 769 people
- Sponsor
- Janssen Research & Development, LLC
Psoriasis
Golimumab Plus UVB-311nm in Psoriasis
Golimumab, a TNF-alpha antibody, has been approved in the EC and USA for the treatment of psoriatic arthritis. The aim of this study is to determine in a randomized half-side comparison whether additional narrowband UVB-311nm…
- Trial name
- NCT01088698
- Testing
- UVB-311nm radiation
- Where
- Austria
- Volunteers
- 20 people
- Sponsor
- Medical University of Graz
Lung Injury, Acute, Respiratory Distress Syndrome, Adult
Study of Enbrel (Etanercept) for the Treatment Sub-Acute Pulmonary Dysfunction After Allogeneic Stem Cell Transplant
The purpose of this study is to determine the effectiveness of etanercept in the treatment of patients with sub-acute lung injury following a bone marrow transplant.
- Conditions
- Lung Injury, Acute, Respiratory Distress Syndrome, Adult, Bronchiolitis Obliterans
- Trial name
- NCT00141726
- Testing
- Etanercept
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of Michigan Rogel Cancer Center
Psoriasis
Multicenter Randomized Double Blind Controlled-study to Assess the Potential of Methotrexate Versus Placebo to Improve and Maintain Response to Anti TNF- Alpha Agents in Adult Patients With Moderate to Severe Psoriasis
The overall purpose of this trial is to assess efficacy and safety of the combination of low doses of Methotrexate (MTX) with anti Tumor Necrosis Factor (TNF) alpha to improve initial efficacy and maintenance rate of anti-TNF…
- Trial name
- METHOBIO (NCT02829424)
- Testing
- Methotrexate
- Where
- France
- Volunteers
- 78 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Graft-versus-Host Disease, Stomatitis
Effectiveness of Topical Thalidomide to Treat Chronic Graft-Versus-Host-Disease Related Stomatitis
This study was designed to be conducted in 2 parts. The first part is a pilot study to test the effects of topical thalidomide gel 20mg applied to up to 3 oral ulcers in patients who have developed oral chronic…
- Trial name
- NCT00075023
- Testing
- Thalidomide Gel
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- National Institute of Nursing Research (NINR)
Infection, Rheumatoid Arthritis
A Retrospective Cohort Study on the Risk of Serious Infections in Rheumatoid Arthritis Patients Receiving Tocilizumab
The purpose of this study is to evaluate whether the risk of serious infections in rheumatoid arthritis patients with tocilizumab is higher than in those with tumor necrosis factor inhibitors using the nationwide real-world data.
- Trial name
- NCT04115423
- Testing
- Tocilizumab, Tumor Necrosis Factor Inhibitor (etanercept, infliximab, adalimumab, and golimumab)
- Where
- South Korea
- Volunteers
- 9,508 people
- Sponsor
- Sungkyunkwan University
NHL, Cutaneous T Cell Lymphoma
A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune System
The goal of this trial is to learn if a new drug, BITR2101, works to treat non-Hodgkin lymphoma (NHL) in adults, with CTCL patients being sought in particular. The trial also seeks to learn about the safety of this drug.
- Conditions
- NHL, Cutaneous T Cell Lymphoma, Peripheral T-cell Lymphoma
- Trial name
- NCT06385522
- Testing
- BITR2101
- Volunteers
- 37 people
- Sponsor
- Boston Immune Technologies and Therapeutics
Psoriasis (PsO), Periodontal Disease
Evaluation of TNF-α, IL-17A, and YKL-40 in GCF and Serum of Psoriasis Patients and Healthy Controls
Background: Psoriasis is a chronic inflammatory skin disease that affects 2-3% of the global population and is linked to immune dysregulation and systemic inflammation.
- Trial name
- NCT06897722
- Testing
- TNF-α analysis in GCF, IL-17A analysis in GCF, YKL-40 analysis in GCF
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Zhala Vatankha Sain